Table 2.

Association between 16 reported prostate cancer susceptibility SNPs with prostate cancer–specific survival

Marker SNP	Chromosome	Position*	Alleles†		Frequency of risk allele	HR (95% CI)	P‡
			Reference	Risk allele
rs721048	2p15	63043382	G	A	0.20	1.10 (0.93–1.30)	0.25
rs2660753	3p12	87193364	C	T	0.10	1.15 (0.92–1.44)	0.21
rs9364554	6q25	16075365	C	T	0.33	0.97 (0.84–1.12)	0.63
rs10486567	7p15	27943088	T	C	0.78	0.96 (0.82–1.13)	0.64
rs6465657	7q21	97654263	T	C	0.51	0.87 (0.75–1.00)	0.05
rs16901979	8q24 (2)	128194098	C	A	0.06	0.89 (0.67–1.18)	0.41
rs6983267	8q24 (3)	128482487	T	G	0.56	1.04 (0.91–1.19)	0.58
rs1447295	8q24 (1)	128554220	C	A	0.17	0.95 (0.79–1.15)	0.62
rs1571801	9q33	121506927	G	T	0.31	0.88 (0.75–1.03)	0.11
rs10993994	10q11	51219502	C	T	0.43	0.94 (0.82–1.08)	0.39
rs4962416	10q26	126686862	A	G	0.24	0.96 (0.82–1.13)	0.65
rs10896449	11q13	68751243	A	G	0.49	0.99 (0.86–1.13)	0.83
rs4430796	17q12	33172153	C	T	0.61	0.91 (0.79–1.05)	0.20
rs1859962	17q24	66620348	T	G	0.54	1.03 (0.89–1.18)	0.69
rs2735839	19q13	56056435	A	G	0.88	0.94 (0.77–1.15)	0.54
rs5945619	Xp11	51258412	A	G	0.42	0.88 (0.72–1.07)	0.20

NOTE: Association between genotypes and prostate cancer – specific survival was assessed in a Cox regression model assuming an additive genetic effect. In each regression model, covariates representing age, clinical stage, biopsy Gleason sum, diagnostic serum PSA level, and nodal and distal metastases were included.

Abbreviations: HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.

^*Based on build 35.

^†Risk alleles are based on previously published studies.

^‡P value from a score test in Cox regression analysis.